Blood Thinner Class Action Lawsuits in New York

Xarelto (rivaroxaban) and Eliquis (apixaban) have faced major litigation over uncontrolled bleeding risks that manufacturers allegedly failed to adequately disclose. Pradaxa (dabigatran) was the subject of an earlier wave of lawsuits that resulted in a multi-million dollar settlement. If you were prescribed any of these drugs and suffered serious bleeding, stroke, or organ damage, you may have a viable claim.

New York residents who suffered serious injuries — such as uncontrolled internal bleeding, hemorrhagic stroke, or death of a family member — while taking a blood thinner may be eligible to join existing litigation or file an individual lawsuit. Many blood thinner cases proceed as mass tort actions rather than traditional class actions, meaning each plaintiff’s damages are evaluated individually. An attorney can assess whether your injuries qualify.

Under CPLR §214, New York imposes a three-year statute of limitations for personal injury claims, including pharmaceutical injury cases. The clock typically starts when you knew or should have known that your injury was linked to the medication. Because the discovery rule can be complex in drug injury cases, you should consult an attorney as soon as possible to protect your right to sue.

Compensation in blood thinner lawsuits varies widely based on the severity of injury, medical costs, lost income, and pain and suffering. No specific outcome can be guaranteed, but past pharmaceutical litigation in this area has resulted in significant aggregate settlements across large groups of plaintiffs, but individual recovery depends entirely on the specific facts of each person's claim. New York also allows wrongful death claims if a family member died from drug-related complications, which may add additional damages.